NextCure, Inc. Share Price
NXTCNextCure, Inc. Stock Performance
Open $11.01 | Prev. Close $11.72 | Circuit Range N/A |
Day Range $10.97 - $11.01 | Year Range $0.22 - $15.61 | Volume 377 |
Average Traded $10.99 |
NextCure, Inc. Share Price Chart
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NextCure, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
19-Mar-26 | $11.01 | $10.97 | +0.00% |
19-Mar-26 | $11.01 | $10.97 | -6.40% |
18-Mar-26 | $12.38 | $11.72 | -3.90% |
17-Mar-26 | $12.25 | $12.20 | -6.05% |
13-Mar-26 | $13.49 | $12.98 | -5.67% |
12-Mar-26 | $13.69 | $13.76 | +8.05% |
11-Mar-26 | $12.73 | $12.73 | +0.59% |